Bio-Convert Develops QR-02, a Potential Breakthrough in the Treatment of Oral Leukoplakia
Bio-Convert, a subsidiary of Nordicus Partners (OTCQB: NORD), has developed QR-02, a novel oral topical treatment for oral leukoplakia with moderate to severe dysplasia. The treatment addresses a significant market of 15.5 million patients in the U.S. and EU, where 10-30% of cases may develop into oral cancer.
QR-02's key innovation is its mucoadhesive formulation that adheres to the oral cavity for 12-24 hours, compared to traditional treatments lasting only 15-20 minutes. The treatment uses imiquimod, an FDA-approved active ingredient, in a unique oral application format. The product aims to treat and reduce dysplasia levels, potentially offering a curative solution for oral leukoplakia.
Bio-Convert, una filiale di Nordicus Partners (OTCQB: NORD), ha sviluppato QR-02, un innovativo trattamento topico orale per la leucoplachia orale con displasia moderata a grave. Il trattamento si rivolge a un mercato significativo di 15,5 milioni di pazienti negli Stati Uniti e in Europa, dove il 10-30% dei casi può svilupparsi in cancro orale.
La principale innovazione di QR-02 è la sua formulazione mucoadesiva che aderisce alla cavità orale per 12-24 ore, rispetto ai trattamenti tradizionali che durano solo 15-20 minuti. Il trattamento utilizza imiquimod, un principio attivo approvato dalla FDA, in un formato unico di applicazione orale. Il prodotto mira a trattare e ridurre i livelli di displasia, offrendo potenzialmente una soluzione curativa per la leucoplachia orale.
Bio-Convert, una subsidiaria de Nordicus Partners (OTCQB: NORD), ha desarrollado QR-02, un novedoso tratamiento tópico oral para la leucoplasia oral con displasia moderada a severa. El tratamiento aborda un mercado significativo de 15.5 millones de pacientes en EE. UU. y la UE, donde entre el 10-30% de los casos pueden desarrollarse en cáncer oral.
La clave de la innovación de QR-02 es su formulación mucoadhesiva que se adhiere a la cavidad oral durante 12-24 horas, en comparación con los tratamientos tradicionales que solo duran 15-20 minutos. El tratamiento utiliza imiquimod, un ingrediente activo aprobado por la FDA, en un formato único de aplicación oral. El producto tiene como objetivo tratar y reducir los niveles de displasia, ofreciendo potencialmente una solución curativa para la leucoplasia oral.
Bio-Convert는 Nordicus Partners(OTCQB: NORD)의 자회사로, 중등도에서 심각한 이형성증을 동반한 구강 백반증에 대한 혁신적인 경구 국소 치료제인 QR-02를 개발했습니다. 이 치료법은 미국 및 유럽에서 1,550만 명의 환자라는 중요한 시장을 대상으로 하며, 이 사례의 10-30%가 구강암으로 발전할 수 있습니다.
QR-02의 주요 혁신은 점착성 제형으로, 구강 내에 12-24시간 산착되며 전통적인 치료는 15-20분만 지속됩니다. 이 치료제는 FDA 승인 성분인 이미quimod를 독특한 경구 적용 형식으로 사용합니다. 제품은 이형성증 수준을 치료하고 감소시키는 것을 목표로 하여 구강 백반증에 대한 치유 솔루션을 제공할 수 있습니다.
Bio-Convert, une filiale de Nordicus Partners (OTCQB: NORD), a développé QR-02, un nouveau traitement topique oral pour la leucoplasie buccale avec dysplasie modérée à sévère. Ce traitement s'adresse à un marché important de 15,5 millions de patients aux États-Unis et en Europe, où 10-30 % des cas peuvent évoluer vers un cancer oral.
La principale innovation de QR-02 réside dans sa formulation mucoadhésive, qui adhère à la cavité buccale pendant 12-24 heures, comparativement aux traitements traditionnels qui ne durent que 15-20 minutes. Ce traitement utilise de l'imiquimod, un ingrédient actif approuvé par la FDA, dans un format d'application orale unique. Le produit vise à traiter et à réduire les niveaux de dysplasie, pouvant offrir une solution curative pour la leucoplasie buccale.
Bio-Convert, eine Tochtergesellschaft von Nordicus Partners (OTCQB: NORD), hat QR-02 entwickelt, eine neuartige orale topische Behandlung für orale Leukoplakie mit moderater bis schwerer Dysplasie. Die Behandlung zielt auf einen bedeutenden Markt von 15,5 Millionen Patienten in den USA und der EU ab, wobei 10-30% der Fälle sich zu oralen Krebs entwickeln können.
Die Hauptinnovation von QR-02 ist die mucoadhesive Formulierung, die sich für 12-24 Stunden an der Mundhöhle haftet, im Vergleich zu traditionellen Behandlungen, die nur 15-20 Minuten dauern. Die Behandlung verwendet Imiquimod, einen von der FDA genehmigten Wirkstoff, in einem einzigartigen Format zur oralen Anwendung. Das Produkt zielt darauf ab, Dysplasie-Levels zu behandeln und zu reduzieren und könnte potenziell eine heilende Lösung für orale Leukoplakie bieten.
- Addresses large market opportunity of 15.5M patients in US and EU
- Innovative 12-24 hour mucoadhesive formulation vs. traditional 15-20 minute treatments
- Uses FDA-approved active ingredient (imiquimod) in new application
- Potential curative solution for condition with high cancer risk
- Product still requires clinical validation
- No timeline provided for clinical trials or market launch
- No data on treatment efficacy or success rates
BEVERLY HILLS, California, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Bio-Convert ApS (“Bio-Convert”), a subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in supporting Nordic and U.S. life sciences companies in establishing themselves in the U.S. market, announces the groundbreaking development of QR-02, a unique and proprietary oral topical treatment designed to address oral leukoplakia with moderate to severe dysplasia, a potentially precancerous condition affecting millions worldwide.
Addressing a Critical Unmet Medical Need
Oral leukoplakia is characterized by white patches or plaques in the mouth, and when accompanied by dysplasia (abnormal cell growth), it becomes a marker of disease progression. Alarmingly, 10
With 15.5 million oral leukoplakia patients in the U.S. and EU alone, there is an urgent need for an effective treatment to prevent disease progression. Given that
QR-02: A Game-Changing Approach
Bio-Convert’s QR-02 introduces a novel mucoadhesive oral formulation designed to adhere to the oral cavity for an extended period of 12-24 hours—a major advancement over traditional treatments, which last only 15-20 minutes due to the washout effect of saliva. This extended retention period significantly enhances drug efficacy and improves patient outcomes.
QR-02’s active ingredient, imiquimod, is already FDA-approved for treating Actinic Keratosis, External Genital Warts, and Superficial Basal Cell Carcinoma (sBCC)—all superficial skin conditions. However, QR-02 is uniquely formulated for oral application, providing new hope for patients with oral leukoplakia and may also be beneficial in treating conditions that subsequently could occur in such patients.
Potential for a Transformative Impact
The goal of QR-02 is to treat and reduce dysplasia levels, potentially offering a curative solution for oral leukoplakia, an outcome that would mark a significant breakthrough in oral medicine. By treating oral leukoplakia at an early stage, QR-02 may potentially have a positive health impact in patients with collateral symptoms.
Advancing Toward Clinical Validation
Bio-Convert is actively progressing QR-02 through its development pipeline, with plans to validate its efficacy through pilot clinical trials and bring this life-changing treatment to market. As Bio-Convert continues to push the boundaries of oral medicine innovation, QR-02 is a major step forward in preventing oral leukoplakia from developing into more severe conditions.
"We are incredibly proud of this invention and the impact it will have on patients," said Allan Wehnert, CEO & Founder of Bio-Convert. "Our hope is that patients may return to a normal life and, potentially, be cured of their illness."
For further information, contact:
Mr. Henrik Rouf
Chief Executive Officer
Phone +1 310 666 0750
Email hr@nordicuspartners.com
Investor Relations
Jonathan Paterson
Harbor Access Investor Relations
Jonathan.Paterson@Harbor-Access.com
Tel +1 475 477 9401
About Nordicus Partners Corporation
Nordicus Partners Corporation is the only U.S. publicly traded business accelerator and holding company for Nordic life sciences companies. Leveraging decades of combined management experience in domestic and global corporate sectors, Nordicus excels in corporate finance activities including business and market development, growth strategies, talent acquisition, partnership building, capital raising, and facilitating company acquisitions and sales. In 2024, Nordicus acquired
Cautionary Note Regarding Forward-Looking Statements:
This press release may contain forward-looking statements that involve substantial risks and uncertainties. You can identify these statements by the use of forward-looking terminology such as “may,” “will,” “should,” “expect,” “anticipate,” “project,” “estimate,” “intend,” “continue” or “believe” or the negatives thereof or other variations thereon or comparable terminology. You should read statements that contain these words carefully because they discuss our plans, strategies, prospects and expectations concerning our business, operating results, financial condition and other similar matters. We believe that it is important to communicate our future expectations to our investors. There may be events in the future, however, that we are not able to predict accurately or control. Any forward-looking statement made by us in this press release speaks only as of the date on which we make it. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
FAQ
What is Bio-Convert's QR-02 treatment for oral leukoplakia and how does it work?
What is the market size for NORD's oral leukoplakia treatment?
When will Bio-Convert's QR-02 begin clinical trials for NORD?
What advantages does NORD's QR-02 have over existing treatments?
How could QR-02 impact NORD's market position in oral medicine?
